Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...

Drugs for metabolic diseases, vaccines and cancer therapies feature among new product launches this year that could top $1 ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to ...

The investment continues a Novo dealmaking spree to cement its leadership status in the cardiometabolic space, with ...

Novo Nordisk is doubling down on its computational biotech partner Valo Health, expanding their collaboration from 11 ...